Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04106856 · ClinicalTrials.gov registry record · Phase 1
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)
A Phase 1 study of Stage III Pancreatic Cancer AJCC v8 and Stage II Pancreatic Cancer AJCC v8, sponsored by University of Utah.
- Active
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT04106856 is a Phase 1 study of Stage III Pancreatic Cancer AJCC v8 and Stage II Pancreatic Cancer AJCC v8 that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 22 participants, below the 59-participant average among 23 other Stage III Pancreatic Cancer AJCC v8 trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04106856, a Phase 1 study of Stage III Pancreatic Cancer AJCC v8 and Stage II Pancreatic Cancer AJCC v8, is active but no longer recruiting, sponsored by University of Utah.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects of losartan and hypofractionated radiation therapy after chemotherapy in treating patients with pancreatic cancer that may or may not be removed by surgery (borderline resectable) or has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection (locally advanced unresectable). Losartan may improve blood flow and allows for better tissue oxygenation. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving losartan and hypofractionated radiation therapy may work better in treating patients with pancreatic cancer compared to hypofractionated radiation therapy alone.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- RADIATION Hypofractionated Radiation Therapy
- DRUG Losartan
- DRUG Losartan Potassium
Study Locations (1)
Utah
- Huntsman Cancer Institute/University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-08-08 |
| Est. Completion | 2026-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04106856
The ClinicalTrials.gov registry entry for NCT04106856 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 59-participant average among 23 other Stage III Pancreatic Cancer AJCC v8 trials with a reported enrollment target (63% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Stage III Pancreatic Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04106856 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT04106856 about?
NCT04106856 is a clinical study titled "Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)". This phase I trial studies the side effects of losartan and hypofractionated radiation therapy after chemotherapy in treating patients with pancreatic cancer that may or may not be removed by surgery (borderline resectable) or has spread from its original site of growth to nearby tissues or lymph no...
What is the current status of trial NCT04106856?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2019-08-08. Estimated completion is 2026-08-08.
What conditions does trial NCT04106856 study?
This clinical trial studies the following conditions: Stage III Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Stage IIA Pancreatic Cancer AJCC v8.
What interventions are being tested in trial NCT04106856?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Hypofractionated Radiation Therapy (RADIATION), Losartan (DRUG), Losartan Potassium (DRUG).
Who is sponsoring clinical trial NCT04106856?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04106856 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Pancreatic Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
RECRUITING · Phase 1
-
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
RECRUITING · Phase 1
-
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
RECRUITING · Phase 1
-
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
RECRUITING · Phase 1
-
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
RECRUITING · Phase 1
-
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Stage III Pancreatic Cancer AJCC v8
All registered trials for this condition
Stage II Pancreatic Cancer AJCC v8
All registered trials for this condition
Utah
All trials with a study site in Utah
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.